AGMB

AgomAb Therapeutics N.V. American Depositary Shares

News

seekingalpha.comAgomAb Therapeutics: High Risk, High Reward Stockseekingalpha.comJun 4

globenewswire.comAgomab Announces Results of Annual General Meetingglobenewswire.comMay 27

globenewswire.comAgomab to Participate in Upcoming Conferencesglobenewswire.comMay 14

globenewswire.comAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlookglobenewswire.comApr 23

Trade AGMB

About AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

CEO: Tim Knotnerus
IPO Date: May 29, 2024

Market Data

Open: $10.10
High: $11.41
Low: $10.10
Volume: 189K
Avg Volume: 139.6K
52W High: $17.45
52W Low: $8.75

Valuation

Market Cap: $541M
Enterprise Value: $471M
Dividend Yield: 0.00%

Financials

Revenue: $0
Net Income: $-46M

Events

EarningsSep 2

EPS est. -0.39227